Phase I trial of isatuximab monotherapy in the treatment of refractory multiple myeloma

This phase I dose-escalation/expansion study evaluated isatuximab (anti-CD38 monoclonal antibody) monotherapy in patients with relapsed/refractory multiple myeloma (RRMM). Patients progressing on or after standard therapy received intravenous isatuximab (weekly [QW] or every 2 weeks [Q2W]). The prim...

Descripción completa

Detalles Bibliográficos
Autores principales: Martin, Thomas, Strickland, Stephen, Glenn, Martha, Charpentier, Eric, Guillemin, Hélène, Hsu, Karl, Mikhael, Joseph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6440961/
https://www.ncbi.nlm.nih.gov/pubmed/30926770
http://dx.doi.org/10.1038/s41408-019-0198-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6440961/
https://www.ncbi.nlm.nih.gov/pubmed/30926770
http://dx.doi.org/10.1038/s41408-019-0198-4

Ejemplares similares